Drugs / DSP-3077
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06891885 | Apr 2026 → Oct 2028 expected | retinitis pigmentosa | Sumitomo Pharma America, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-11-29 | Sumitomo Pharma America, Inc. | Regulatory Initiation of Phase1/2 Study on Allogeneic iPS Cell-derived Retinal Sheet for Retinitis Pigmentosa in the United States sumitomo-pharma.com ↗
The IND application, submitted on October 25, 2024, received FDA approval after a 30-day review, and preparations for initiating the clinical study are being finalized. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-29 | Sumitomo Pharma America, Inc. | Initiation of Phase1/2 Study on Allogeneic iPS Cell-derived Retinal Sheet for Retinitis Pigmentosa in the United States sumitomo-pharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DSP-3077 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06891885 ↗ |
| Modality | Cell therapy | “allogeneic induced pluripotent stem cell (iPSC)-Derived Retinal Sheets (DSP-3077)” NCT06891885 ↗ |
| Route | Other | “administered with a single subretinal uniocular injection” NCT06891885 ↗ |